BMO Capital initiated coverage of Protagonist Therapeutics (PTGX) with an Outperform rating and $62 price target The firm says Protagonist is leveraging its peptide technology platform to address hematology and immunology disorders. It expects the shares to continue to appreciate on clinical de-risking of its pipeline over the next 12 months with several catalysts for rusfertide and JNJ-2113. Protagonist can deliver oral options in mega-blockbuster categories currently dominated by injectables, contends BMO.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities
- Protagonist Therapeutics price target raised to $67 from $51 at BTIG
- Protagonist Therapeutics selects PN-881 as development candidate
- Protagonist and JNJ say icotrokinra study for PsO meets endpoint
- Protagonist Therapeutics Reports Strong Financial Turnaround